MSI-low, a real phenomenon which varies in frequency among cancer types

Sarah E R Halford, Elinor J. Sawyer, Maryou B. Lambros, Patricia Gorman, Nicola D. Macdonald, Ian C. Talbot, William D. Foulkes, Cheryl E. Gillett, Diana M. Barnes, Lars A. Akslen, Kwok Lee, Ian J. Jacobs, Andrew M. Hanby, Trivadi S. Ganesan, Helga B. Salvesen, Walter F. Bodmer, Ian P M Tomlinson, Rebecca R. Roylance

    Research output: Contribution to journalArticlepeer-review

    Abstract

    This study assessed whether low-level microsatellite instability (MSI-L) is a phenomenon specific to colorectal cancers or is also present in other tumour types. Breast (grade III ductal and lobular), endometrial and ovarian carcinomas, as well as colorectal cancers, were analysed for MSI-L using eight microsatellite markers. The markers were selected from a panel that had previously been shown to be sensitive for the detection of MSI-L in colorectal cancers. It was found that MSI-L was present in 30 of 87 (35%) colorectal cancers, 2 of 59 (3%) grade III breast carcinomas, 1 of 35 (3%) lobular breast cancers, 16 of 50 (32%) endometrial cancers, and 9 of 34 (26%) ovarian cancers. These results suggest that MSI-L is a very rare occurrence in breast carcinomas, but does occur as a real phenomenon in colorectal, endometrial, and ovarian carcinomas, which are all part of the hereditary nonpolyposis colon cancer (HNPCC) syndrome. PCR artefact was also found to masquerade as MSI-L; criteria for the assessment of MSI-L are suggested to eliminate this problem. Copyright © 2003 John Wiley & Sons, Ltd.
    Original languageEnglish
    Pages (from-to)389-394
    Number of pages5
    JournalJournal of Pathology
    Volume201
    Issue number3
    DOIs
    Publication statusPublished - Nov 2003

    Keywords

    • Breast cancer
    • Colorectal cancer
    • Endometrial cancer
    • HNPCC
    • Microsatellite instability
    • MSI-L
    • MSI-low
    • Ovarian cancer

    Fingerprint

    Dive into the research topics of 'MSI-low, a real phenomenon which varies in frequency among cancer types'. Together they form a unique fingerprint.

    Cite this